Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RMTI: I've just begun looking into Rockwell Medical.
From Yahoo PR (https://finance.yahoo.com/news/rockwell-medical-reports-fourth-quarter-210100140.html): Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis
Product development pipeline: http://www.rockwellmed.com/bio-pharma-product-pipeline.htm
They reported yesterday:
Sales up 3.5%, gross profit up 25%, R&D is under control, a loss decrease of 56% to 21.3M.
CC yesterday: [ http://edge.media-server.com/m/p/iofj8ijn ]
They just received FDA approval for Triferic for iron replacement and maintenance of hemoglobin in hemodialysis patients. Expect to launch Trimeric in 4-5 months; pricing negotiations underway.
Baxter just became a commercial partner and gave Rockwell $35M. They also received 8.4M cash from warrant conversion, 55M cash from equity financing, and paid off LT debt.
The company is expanding facilities on West Coast.
Stock is at the 50 day which (bullishly) just crossed the 200 day and the stock is under accumulation.
Though there still could be delays in getting Triferic to market, the stock price is projected (by Stifle using DCF) to double. I think a reasonable price target range is $16-19 as they close in on marketing Triferic. That would be a 55-85% gain as the price is 10.28 as I type.
Kind regards,
Minding
Note: The offering was predicted to close on Tuesday, March 3.
Also a reminder: If you planned to sell close to $3 yesterday, today's offering diluted the shares which means your target price may need revision.
Kind regards,
Minding
=========
From http://www.wsnewspublishers.com/report-on-most-unpredictable-behavior-of-collabrx-inc-nasdaqclrx-midday-alert-on-workday-nysewday-intralinks-holdings-inc-nyseil-merge-healthcare-incorporated-nasdaqmrge/151570/
CollabRx, Inc. (NASDAQ:CLRX)’s shares drowned -37.67% and is now trading at $1.39, soon after the news release that a recognized leader in cloud-based expert systems to inform healthcare decision-making, declared the pricing of an underwritten public offering of 2,362,205 shares of its ordinary stock at a price to the public of $1.27 per share. Gross proceeds to CollabRx from this offering are about $3,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by CollabRx. CollabRx has granted the underwriter a 45-day option to purchase up to an additional 354,330 shares of ordinary stock to cover over-allotments, if any. The offering is predictable to close on March 3, 2015, subject to customary closing conditions.
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
CollabRx, Inc. (NASDAQ:CLRX), is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
Yup. I don't normally think quite this much, but remember I got this email from my friend who gave me information I wouldn't have had.
Kind regards,
Minding
Breezy, you may be right but there's nothing wrong with thinking. Not thinking is a bad idea.
To those of us who own CLRX, we'll 'live or die' by the price action. For those who haven't bought or are thinking of buying more, a little fore-thought can go a long way.
Kind regards,
Minding
One way to see if anyone's angry at or playing games with CLRX is to compare short interest from yesterday and today once today's numbers are posted at http://online.wsj.com/mdc/public/page/2_3062-nasdaqshort-highlites.html
Kind regards,
Minding
I suggest caution to anyone about buying CLRX right now.
After buying shares today, I learned today from a friend, a retired fund manager who has been investing for 30 years, that Aegis has created a speciality in trying to financially support long shot medical technology stocks and might be employing a trick in the trade: Brokers create demand in one stock to create cash to support the next stock, a bit like an airplane scheme. For Aegis BIOC was first, CLRX was second. They are already onto a third SGNL.
Is Aegis employing this trick? Hard to say for certain. As my friend said, "Most of these companies do have POTENTIALLY hot technology---and that is how they raise money and get people to buy into the dream. That is the job of stock brokers. I'm not against rasing money for very speculative startups but you have to know what you are buying. The rewards can be enormous if successful---but in reality few are successful."
Know what you're buying -- that's the point. Look at all three stocks and you'll see they all ended the day at or near their lows. Why would that be? It could just be market forces generally or the fact they all had good days yesterday and need to retrace a little.
My concern, after watching the action of CLRX all day, is that Aegis, with the second CLRX offering last night (which is almost unheard of) made some hedge funds very, very angry.
IMHO not a good time to be entering.
Kind regards,
Minding
This stock has behaved in a peculiar way today. The latest offering sold out without ever reaching the offering price of 1.27. The stock subsequently dropped to the (so far) low of the day. It has then moved sideways ... despite the overwhelming enthusiasm ... and has now revisited the low of the day at the end of the day. What could possibly explain this? Why wouldn't it have moved up by now given yesterdays action after the first offering closed?
My suspicion is one of two two things is going on ... perhaps both:
Either the broker is playing with this ... you know, the one that issued two offerings inside a week, that's been accused of buying at the low yesterday and selling at the high.
Or they've met up with some very angry investors who are shorting the stock because the broker pulled these shenanigans.
But that's a guess on my part. Time will tell if big energies are fighting with the broker and are going to keep this stock down.
Either way I'm convinced it's acting in a very peculiar way today.
Kind regards,
Minding
Nicely written but not news:
Kind regards,
Minding
-------------------
From http://traders350.com/elite-pharmaceuticals-inc-otcmktseltp-updates-on-phase-iii-study-of-eli-200/721676/
Elite Pharmaceuticals Inc (OTCMKTS:ELTP) Updates On Phase III Study Of ELI-200
BY LYLE MILLIGAN • FEBRUARY 26, 2015
Elite Pharmaceuticals Inc (OTCMKTS:ELTP) provided guidance on its Phase III trial for ELI-200. It is an abuse-deterrent opioid product. It has filed a study protocol to the FDA. It will begin with dosing for the study as soon as it receives FDA comments on the protocol. The comments are expected to come by mid-March following that dosing of study will be completed within a period of eight weeks.
The Phase III study
It is a randomized, double-blind, multiple-dose, placebo-controlled, parallel group and multi-center study to assess the safety and efficacy of ELI-200. The drug is meant for the treatment of patients with moderate to severe pain resulting from surgery. The trial will have almost 150 patients. Elite expects to file the NDA for ELI-200 in 3Q and, therefore, anticipates the NDA review to be completed by early 2016.
The additional studies
Elite Pharmaceuticals will conduct two additional studies to support product labeling. The first one will be a phase one, randomized, single-dose, open-label and three-way crossover trial to compare the bioavailability of lead candidate to the reference product as per the Fed guidelines in healthy people. Dosing of Phase one has been completed.
The second study
It is a randomized, multiple-dose, parallel group, and double-blind study to assess potential withdrawal effects after administration of ELI-200 compared to the reference drug in methadone-maintained opioid-dependent patients. The dosing of the second study has been initiated. Reports and results from both trials are expected to be presented before the completion of the Phase III study.
The management view
Elite Pharmaceuticals’s CEO, Nasrat Hakim, said that positive guidance is received from the FDA. There is a clear regulatory road ahead for ELI-200. The filing date is anticipated in 3Q2015. The FDA review leading to approval of ELI-200 is expected to be completed by 2016. The company is expanding its manufacturing facility so as to support the launch of ELI-200.
Thanks! It's useful to provide links:
http://www.sec.gov/Archives/edgar/data/931059/000121390015001384/sc13g0215alpha_collabrx.htm
Kind regards,
Minding
This is more of what I was expecting; much closer to 1.27. However it's very interesting to note this is happening at the 6M volume mark halfway through the day.
Kind regards,
Minding
Shotor, I agree. I'm just surprised so many have been expecting lower prices are out of reach.
I expect to see more buys on the bid than the ask and for the price to drop. Time will tell if I'm wrong.
Kind regards,
Minding
BR or anyone here, a question. The offering is priced at 1.27. Why are investors buying it above 1.45? I expect it to drop lower on the open. Of course I may very well be mistaken.
Kind regards,
Minding
cleverox, hanks for your perspective.
Best,
Minding
PESI: cleverox, terrific write-up of an insightful discussion. Thanks.
I have two questions on the periphery:
Do you or anyone have a sense of the impact should Chalk River somehow remain open? I know that seems remote, but would that be a nail in the coffin for PESI's approach? I suspect it would merely slow them down given the advantages of their approach.
I'm also wondering if there might be a non-public effort to replace Chalk River. Has anyone heard anything?
Thanks.
Kind regards,
Minding
KINS: FYI
This may not amount to much, hard to know, but after Sandy, regulations were written including "accelerated claims investigation and settlement requirements and mandatory participation in non-binding mediation proceedings funded by the insurer." The New York State Department of Financial Services is investigating KICO following Sandy because of a large # of complaints. The company hasn't heard the outcome yet.
Kind regards,
Minding
CVRP: Agree on all you wrote. They're on my watch list ... I want to see a little their intentions begin to materialize and also learn why water and coffee were down though I suspect competition that isn't going away ... and I thank you for bringing them to my attention.
Kind regards,
Minding
CRVP: 2013-2014 the big difference was in the Other category. Water and Coffee were down.
From their 10Q:
Other – Commissions earned on brokered sales, an arrangement that was a result of the October 2013 acquisition, accounted for the increase in sales. Fees that are charged to offset energy costs for delivery and freight, raw materials, and bottling operations decreased 4% based on the market price of diesel fuel and the number of customers paying those fees.
Kind regards,
Minding
Thanks Magnetics.
SGLB is a bleeder. All the effort seems to be going into the technology and as a result the company doesn't appear to be well-managed.
The only hope is for a staggeringly lucrative contract or contracts. There's no sign that will happen in the near future.
So it becomes a question of money. Is there enough? Will there be enough? How will SGLB get more? What effect will this have on your shares? (Dilution is a four-letter word.) Judging from the price drop investors are giving up.
The thing to remember is that the technology should be quite valuable once it reaches the market and once customers show up. However this is a new industry. The potential customer base will build slowly. IMO only government contracts will save SGLB. In the meantime it will cost you to wait.
Kind regards,
Minding
Magnetics, two investment questions:
What was your reason for buying as the stock dropped?
Have you concluded anything has fundamentally changed since your last purchase?
Kind regards,
Minding
Hadn't considered the flame as being a feature. Very good point!
For some the fact that Emerson's products sell -- Walmart is still Walmart -- is the bottom line. Consumers need a variety of price points after all.
I have a slew of prospects but it's very difficult to find any I like through-and-through. That usually leaves me holding few stocks in general and holding them longer.
Kind regards,
Minding
hweb2, I don't know if you'll find this all that relevant given the companies position on litigation in their 10-Q but I went to a few review sites and some of their products look to be of very low quality.
http://www.consumeraffairs.com/homeowners/emerson_microwave.html
http://emerson-electronics.pissedconsumer.com/
Kind regards,
Minding
Couch, many like you like his enthusiasm. I never liked Pete Carroll but a lot of people have. That's a style issue and not all that important. So I'm not suggesting he shouldn't give investors information.
And I'm really happy seeing no mistakes. (I don't count the delays as mistakes, though they've been unfortunate.) At this point I'm waiting on the milestones.
Minding
Makes sense Couch.
I've gotten burned too many times with sure things, including CEOs making promises they couldn't keep. I like and Nasrat, but as a first-time CEO thought he should lower the volume a bit. Unlike you I feel wary hearing "Nothing can stop us." In his most recent update he sounded more muted to me. And though I wondered why, I was happy about that. My hope is that he knows he doesn't need to create investor enthusiasm; it's time to let results do the talking.
I will buy with each milestone reached.
Best,
Minding
We're not far off Dr_L. In my workup I added 6 mths to lasers schedule; end of 2016.
I'd be delighted if they met lasers prediction and quite content if instead they hit early 2017. At this point, it's all guesswork so no one can be faulted for the differences.
Kind regards,
Minding
Thanks laser for sharing that experience. I probably fall somewhere between your timeline and one I hope Dr_L will produce since I consider delays inevitable.
Best,
Minding
Dr_L you could certainly be correct on 1, 2, or all 3 points. Perhaps you would handicap his schedule by giving us an adjusted timeframe? It would be of value to any investor to compare both.
Thanks,
Minding
True enough Dr_L. Knowing this is enough. I don't think he's far off on, what I think of as, a tentative schedule.
Kind regards,
Minding
Thanks Laser. I came to that understanding after reading post 145760. It's helpful to me to have the clarity of source, as I mentioned to Couch, so I can weight the information.
In this case, even if it had been Nasrat's schedule, I would handicap it. Rarely do things go on-schedule and/or as planned.
That said, things are progressing just fine with ELTP. May they continue to do so!
Kind regards,
Minding
Hey Couch,
Posters here often don't include links when they have them. Of course, as I've said before, they quite often post things as if the information is official when it's not. In either case, I prefer to know so I can appropriately weight the info.
All the best,
George
Laser, great info. Your dates or do you have a link?
Kind regards,
Minding
Me too Couch. Me too.
Minding
Video on Market Makers
For those wishing to understand market makers a little better, here's one explanation:
Share structure: For those interested in a primer.
Kind regards,
Minding
============
From http://microcapclub.com/2012/08/the-importance-of-share-structure/
The Importance of Share Structure
Understanding share structure is an extremely important component of the due diligence process and in determining the value of an equity. This article will provide an introduction to the key principles one should look at when trying to identify whether a share structure is healthy for investors.
The first and more important component is shares outstanding, which is defined as the shares of a corporation that have been authorized, issued, and purchased by investors and are held by them. Though basic mathematics by nature, beginning investors sometime fail to recognize the relevance of shares outstanding when calculating the value of a company. This important component is directly correlated to market capitalization and also inversely correlated to the most important earnings metric, EPS (earnings per share). A higher number of shares outstanding makes it more difficult for a company to increase its profitability on a per share level. Thus, when you look at companies who are relatively young and investing in their growth, it’s important to watch the shares outstanding, whether they’ve been increasing or remaining relatively stagnant. A stagnant shares outstanding in this case is a positive. Companies often fund their growth by selling new shares to raise capital. Though a common practice and in many cases warranted, as an investor, you never want to see your shares suffer further dilution. A share count between 20 mln – 30 mln is healthy for many micro cap companies. I typically do not view shares outstanding as a negative characteristic unless it is approaching 75 mln – 100 mln.
The second component which ties directly into shares outstanding is the available float, and is defined as the total number of shares publicly owned which are available for trading. The difference between shares outstanding and available float lies with those shares held by insiders that are not publicly available for trading. For example, a company may have 20 mln shares outstanding but only 15 mln may be available for trading. The other 5 mln shares may be held by management or an institutional investor. Float is an important factor to consider when you are looking at a stock, its trading liquidity, and when attempting to determine whether recent trading volumes have been normal or abnormal. A stock with a low float may have liquidity issues and as you build a position of significant size, liquidity is always an important risk factor to consider. I typically view both lower float stocks, as well as companies who have a large portion of their shares held by insiders or institutions as a positive characteristic.
The third component that is important is insider ownership. An investor who owns more than 5% is required to disclose publicly with the SEC. Insider ownership is the percentage of common stock held by all officers and directors as a group. This statistic is important to watch for many reasons. First and foremost, incentivized management teams should have an alignment of interest and thus when they do so, it is viewed favorably. I always question why management teams are not incentivized with equity in their company. Being so close to the story, if they believe in it, why would they not want to own shares and even further, if they don’t want to, why should you? As a rule of thumb, avoid companies where management is not invested themselves. Taking it a step further, insider activity is also very interesting and relevant to watch. Most insider trading activity is either defined as an open market purchase/sale, a purchase or sale as a part of a 10b5-1 plan (predetermined activity and thus not as noteworthy), or activity driven by the execution or conversion of options/warrants. Open market purchases and sales are by far the most notable. When I look at companies, I like to see management with a large stake in the company – 10% or more especially when you look at micro cap companies. Open market purchases are viewed very favorably as they speak to confidence in the story. Companies with little or no insider ownership should be looked at with an eye of caution.
Finally, the fully diluted shares outstanding number is also very important to make note of. Often times, small and micro cap companies fund their growth through the issuance of options and warrants. A company with a relatively low shares outstanding, may have a very large number of options and/or warrants issued which can lead to significant dilution in the years to come. It is very important that investors who are performing initial due diligence look at the fully diluted shares number as it can materially change their forecasting model of future EPS growth. Not only can the fully diluted amount be materially higher, but significant issuance of warrants and options can sometimes lead to an overhang on shares at certain exercise price levels.
In summary, share structure is an important characteristic to research during the due diligence process. Companies that issue shares, options, and warrants are diluting their share count and that is never viewed favorably by investors. Companies who have abnormally large shares outstanding may struggle to reduce them. Small cap investors typically desire growth and would rather see companies utilize free cash flow to fuel further growth, rather than using resources to reduce the share count. In addition, a lower share count can provide flexibility for small companies to strategically use capital markets in the future. Understanding this structure can provide insight into management and their alignment of interest which is very important when assessing management teams. There are many great story stocks but differentiating between the great story without a proper share structure and the great story with a healthy share structure can be the difference between investment success and investment failure.
Thanks Steve! I always like good news.
George
Dropped big in Japan. Can anyone get news from there?
Minding
Wowsa. The opening today is a surprise. Anyone finding any news?
Minding
PESI: Of note in the short term, short interest rises
Kind regards
Minding
============
From http://candlestrips.com/perma-fix-environmental-services-inc-short-interest-climbs-by-30-8/330661/
Perma-Fix Environmental Services, Inc. Short Interest Climbs by 30.8%
Mathew Donald · Feb 12th, 2015 · 0 Comment
Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) reported a rise of 5,846 shares or 30.8% in the short interest. The remaining shorts are 0.2% of the total floated shares. The net short interest, as on January 30,2015, stood at 24,823 shares and the stocks days to cover will be 2 by factoring in the average per day volume of 15,791 shares. On January 15,2015, 18,977 shares were shorted.
PESI witnessed volatile trading session. Investors in Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) discarded the counter and the shares fell 2.19% or 0.1 points in todays trading session. Upon opening the transactions at $4.44, the counter maintained a trading range between $4.44 and $4.6089 before the day culminated at $4.46. Even as the price action was dull, the volume figure touched 48,287 shares. The previous close of the share price was $4.56. The shares have a 52-week peak value of $5.86 while the yearly price nadir is registered at $3.22. With around 11,469,000 shares in outstanding, the current market cap of the company is $51 million.
Shares of Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) appreciated by 1.69% during the past week but lost 2.54% on a 4-week basis. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 1.31%. Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) has underperformed the index by 3.05% in the past 4 weeks. Investors should watch out for further signals and trade with caution.
Perma-Fix Environmental Services, Inc. is an international environmental and technology know-how company. The Company operates in two segments: The Treatment Segment (Treatment) and the Services Segment (Services). The Company service research institutions, commercial companies, public utilities, and governmental agencies nationwide, including the United States Department of Energy (DOE) and the United States Department of Defense (DOD). The Treatment Segment consists of treatment, processing, and disposal services of nuclear, low-level radioactive, mixed, hazardous and non-hazardous waste. The Services Segment consists of on-site waste management, technical, and consulting services. On August 12, 2011, it completed the sale of Perma-Fix of Fort Lauderdale, Inc. On October 14, 2011, it completed the sale of Perma-Fix of Orlando, Inc. On October 31, 2011, it completed the acquisition of Safety & Ecology Holdings Corporation and its subsidiary, Safety & Ecology Corporation.
PESI: Of note in the short term, short interest rises
Kind regards
Minding
============
From http://candlestrips.com/perma-fix-environmental-services-inc-short-interest-climbs-by-30-8/330661/
Perma-Fix Environmental Services, Inc. Short Interest Climbs by 30.8%
Mathew Donald · Feb 12th, 2015 · 0 Comment
Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) reported a rise of 5,846 shares or 30.8% in the short interest. The remaining shorts are 0.2% of the total floated shares. The net short interest, as on January 30,2015, stood at 24,823 shares and the stocks days to cover will be 2 by factoring in the average per day volume of 15,791 shares. On January 15,2015, 18,977 shares were shorted.
PESI witnessed volatile trading session. Investors in Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) discarded the counter and the shares fell 2.19% or 0.1 points in todays trading session. Upon opening the transactions at $4.44, the counter maintained a trading range between $4.44 and $4.6089 before the day culminated at $4.46. Even as the price action was dull, the volume figure touched 48,287 shares. The previous close of the share price was $4.56. The shares have a 52-week peak value of $5.86 while the yearly price nadir is registered at $3.22. With around 11,469,000 shares in outstanding, the current market cap of the company is $51 million.
Shares of Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) appreciated by 1.69% during the past week but lost 2.54% on a 4-week basis. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 1.31%. Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) has underperformed the index by 3.05% in the past 4 weeks. Investors should watch out for further signals and trade with caution.
Perma-Fix Environmental Services, Inc. is an international environmental and technology know-how company. The Company operates in two segments: The Treatment Segment (Treatment) and the Services Segment (Services). The Company service research institutions, commercial companies, public utilities, and governmental agencies nationwide, including the United States Department of Energy (DOE) and the United States Department of Defense (DOD). The Treatment Segment consists of treatment, processing, and disposal services of nuclear, low-level radioactive, mixed, hazardous and non-hazardous waste. The Services Segment consists of on-site waste management, technical, and consulting services. On August 12, 2011, it completed the sale of Perma-Fix of Fort Lauderdale, Inc. On October 14, 2011, it completed the sale of Perma-Fix of Orlando, Inc. On October 31, 2011, it completed the acquisition of Safety & Ecology Holdings Corporation and its subsidiary, Safety & Ecology Corporation.
I'd like to bow out of the discussion. I've made my points. You and others have made their points, but we've reached different conclusions.
Kind regards,
Minding
sallardyce1, my focus is convincing myself that SGLB has capable management, which is at the moment an open question to me ... I don't know if they do or don't and would like clarification.
I'm onboard with a capable management doing what they determine is prudent and/or necessary.
For the record, Alan won't visit management without more posters here asking him to do so.
Kind regards,
Minding